Trial Profile
Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Abbott Laboratories; AbbVie
- 03 Nov 2021 Status changed from active, no longer recruiting to completed.
- 08 Oct 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.
- 25 Jan 2021 Planned End Date changed from 4 Nov 2020 to 30 Sep 2021.